Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 8/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23419612 | 0.89 | ALDH1A1 (0.44) | ALDH1A1MAPTHPGDMCL1L3MBTL1 | |
| SCHEMBL21472794 | 0.89 | PKM (0.47) | PKMALDH1A1MAPTHPGDTSHR | |
| SCHEMBL21231247 | 0.81 | ALDH1A1 (0.63) | PKMALDH1A1MAPTHPGDTSHR | |
| SCHEMBL21477763 | 0.80 | ALDH1A1 (0.58) | PKMALDH1A1MAPTHPGDTSHR | |
| SCHEMBL21472729 | 0.79 | ALDH1A1 (0.45) | ALDH1A1MAPTHPGDMCL1L3MBTL1 | |
| SCHEMBL21842783 | 0.78 | ALDH1A1 (0.46) | PKMALDH1A1MAPTHPGDTSHR | |
| SCHEMBL23419623 | 0.77 | ALDH1A1 (0.46) | PKMALDH1A1MAPTHPGDTSHR | |
| SCHEMBL21472702 | 0.76 | ALDH1A1 (0.48) | PKMALDH1A1MAPTHPGDTSHR | |
| SCHEMBL21472705 | 0.76 | ALDH1A1 (0.45) | PKMALDH1A1MAPTHPGDTSHR | |
| SCHEMBL21230890 | 0.74 | ALDH1A1 (0.46) | PKMALDH1A1MAPTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | PKM 4139/4885ALDH1A1 4722/4885MAPT 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.